Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171418 · ClinicalTrials.gov registry record · Phase 3
Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 54
- Enrollment target
NCT00171418 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 54 participants.
The verdict
NCT00171418, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 54 participants
- Enrollment target
Study Summary
Study to assess the effects of adding tegaserod to PPI therapy results in clinically meaningful improvement of GERD symptoms in patients with incomplete relief of symptoms on daily PPI therapy alone.
Interventions
- DRUG Tegaserod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2003-06 |
| Est. Completion | 2005-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00171418
The ClinicalTrials.gov registry entry for NCT00171418 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tegaserod is the first listed.
NCT00171418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00171418 about?
NCT00171418 is a clinical study titled "Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).". Study to assess the effects of adding tegaserod to PPI therapy results in clinically meaningful improvement of GERD symptoms in patients with incomplete relief of symptoms on daily PPI therapy alone.
What is the current status of trial NCT00171418?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 54 participants. The study started on 2003-06. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00171418?
The interventions under investigation include: Tegaserod (DRUG).
Who is sponsoring clinical trial NCT00171418?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.